Fate Therapeutics (FATE)
(Delayed Data from NSDQ)
$3.55 USD
+0.03 (0.85%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $3.56 +0.01 (0.28%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Income Statements
Fiscal Year end for Fate Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 64 | 96 | 56 | 31 | 11 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 64 | 96 | 56 | 31 | 11 |
Selling & Adminstrative & Depr. & Amort Expenses | 254 | 405 | 273 | 160 | 111 |
Income After Depreciation & Amortization | -191 | -308 | -217 | -128 | -101 |
Non-Operating Income | 30 | 27 | 5 | -45 | 4 |
Interest Expense | 0 | 0 | 0 | 0 | 2 |
Pretax Income | -161 | -282 | -212 | -173 | -98 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -161 | -282 | -212 | -173 | -98 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -161 | -282 | -212 | -173 | -98 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -176 | -292 | -202 | -120 | -98 |
Depreciation & Amortization (Cash Flow) | 14 | 16 | 15 | 8 | 2 |
Income After Depreciation & Amortization | -191 | -308 | -217 | -128 | -101 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 98.41 | 96.83 | 94.75 | 82.39 | 68.19 |
Diluted EPS Before Non-Recurring Items | -1.64 | -2.91 | -2.36 | -1.52 | -1.44 |
Diluted Net EPS (GAAP) | -1.64 | -2.91 | -2.24 | -2.10 | -1.44 |
Fiscal Year end for Fate Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 6.77 | 1.93 | 1.68 | 1.94 | 0.93 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 6.77 | 1.93 | 1.68 | 1.94 | 0.93 |
SG&A, R&D, and Dept/Amort Expenses | 51.85 | 53.00 | 49.76 | 53.23 | 63.50 |
Income After SG&A, R&D, and Dept/Amort Expenses | -45.08 | -51.07 | -48.08 | -51.29 | -62.57 |
Non-Operating Income | 6.66 | 3.06 | 3.95 | 6.11 | 9.81 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -38.43 | -48.00 | -44.12 | -45.17 | -52.76 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -38.43 | -48.00 | -44.12 | -45.17 | -52.76 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -38.43 | -48.00 | -44.12 | -45.17 | -52.76 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 117.47 | 101.10 | 98.61 | 98.57 | 98.40 |
Diluted EPS Before Non-Recurring Items | -0.33 | -0.47 | -0.45 | -0.46 | -0.54 |
Diluted Net EPS (GAAP) | -0.33 | -0.47 | -0.45 | -0.46 | -0.54 |